NewsEvents

Your Yourlocation: Home > Umeclidinium-Vilanterol Combination Better Than Tiotropium Bromide(136310-93-5) Monotherapy for COPD

Tiotropium bromide(136310-93-5) is a specific selective anticholinergic drug that inhibits the smooth muscle M3 receptor, produces bronchodilator, and maintains its bronchiectasis during 1 year of administration, with no tolerance to occur Improve symptoms of dyspnea in COPD patients.

Umeclidinium-Vilanterol combined with treatment of COPD to improve lung function is superior to tiotropium monotherapy. The study was published in the October 14 issue of the Journal of Respiratory Medicine.

Previous studies have shown that long-acting muscarinic receptor antagonist (LAMA) combined with long-acting beta2 receptor agonists significantly improve lung function in patients with COPD compared with single therapy.

In this study, Dr. Reza Maleki-Yazdi from Toronto, Canada, and his team compared the 905 COPD patients in the Phase 3 clinical study to compare the efficacy of combination therapy with tiotropium bromide(136310-93-5) and tiotropium monotherapy. The approximately half of the patients in both groups began to inhale glucocorticoids at the end of treatment 30 days before admission.

Compared with tiotropium bromide(136310-93-5) monotherapy, patients receiving Umeclidinium-Vilanterol combined therapy increased 0.112 L on day 169 FEV1.

The total score of the George questionnaire in the combined treatment group was significantly improved, and the inhaled hormone was reduced by 0.5 puff /day.

The investigators said there was no significant difference between the two groups in treatment-related adverse events.

"These results have increased evidence to support dual bronchial dilatation in the treatment of symptomatic COPD patients," they concluded.

LABA /LAMA combined with other studies of varying degrees of COPD and in combination with inhaled corticosteroids may help to expand the empirical treatment of Umeclidinium-Vilanterol, a further clinical benefit of this combination in clinical practice In determining its preferred position in the treatment of COPD mode. "They added.

Umeclidinium-Vilanterol combination therapy has been approved by the United States and the European Union once a day to maintain treatment of COPD.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved